Cogent Biosciences
Watchlist
Cogent Biosciences (COGT): Acquisition in the Peer Group and JPMorgan Sees 300% Price Potential!
Reading Time: 2 minutes
In addition to study data and analyst comments, venture capital in biotechs is now also seeing M&A fantasies again, following Sanofi's announcement that it intends to acquire Blueprint Medicines for $129 per share or approximately $9.1 billion. Blueprint Medicines is a biotechnology company focusing on the development of precision therapies for cancer and hematological diseases caused by specific genetic mutations and aberrant kinase signaling pathways. A direct competitor is, for example, Cogent Biosciences (COGT) . Biotech focusing on precision...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
